U
MDGL icon

UBS’s Madrigal Pharmaceuticals MDGL Stock Holding History

UBS’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-91
Closed -$17K – 10630
2013
Q4 		$17K Sell
91
-32
-26% -$5.86K ﹤0.01% 8345
2013
Q3 		$27K Buy
123
+117
+1,950% +$24.9K ﹤0.01% 7674
2013
Q2 		$1K Buy
+6
New +$1.56K ﹤0.01% 10023

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's MDGL Position: Q3 2014 in Review

UBS held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2014 at 3,171 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #4666.

UBS first reported a position in MDGL in Q2 2013 and has held it in 6 quarters since. The position peaked at $582K in Q4 2013. 92 funds tracked by Wall St. Rank hold MDGL as of Q3 2014.

  • UBS held 3,171 shares of Madrigal Pharmaceuticals worth $334K as of Q3 2014.
  • UBS left its Madrigal Pharmaceuticals share count unchanged in Q3 2014.
  • Madrigal Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4666 holding.
  • UBS first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Madrigal Pharmaceuticals position peaked at $582K in Q4 2013.
  • 92 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.